Silvan Tuerkcan
Stock Analyst at Citizens JMP
(4.71)
# 759
Out of 4,988 analysts
431
Total ratings
43.2%
Success rate
16.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLLS Cellectis | Downgraded: Hold | n/a | $1.53 | - | 24 | Sep 15, 2026 | |
| RLAY Relay Therapeutics | Reiterated: Buy | $21 → $26 | $18.84 | +38.00% | 38 | Aug 10, 2026 | |
| TSHA Taysha Gene Therapies | Reiterated: Buy | $8 → $11 | $5.02 | +119.12% | 44 | Jun 23, 2026 | |
| ENGN enGene Therapeutics | Downgraded: Hold | n/a | $1.91 | - | 7 | May 8, 2026 | |
| NTLA Intellia Therapeutics | Reiterated: Buy | $28 → $30 | $12.14 | +147.12% | 45 | Apr 28, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterated: Buy | $86 → $80 | $56.56 | +41.44% | 56 | Jan 30, 2026 | |
| NUVB Nuvation Bio | Reiterated: Buy | $8 → $10 | $5.85 | +70.94% | 6 | Nov 20, 2025 | |
| BNTC Benitec Biopharma | Reiterated: Buy | $20 → $22 | $11.02 | +99.64% | 26 | Nov 4, 2025 | |
| FHTX Foghorn Therapeutics | Reiterated: Buy | $9 | $4.14 | +117.39% | 4 | Oct 31, 2025 | |
| IDYA IDEAYA Biosciences | Reiterated: Buy | $45 | $38.41 | +17.16% | 4 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $6 | $0.6178 | +871.19% | 12 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $1.85 | n/a | 12 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $8.91 | n/a | 10 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $4.14 | n/a | 29 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $58.36 | n/a | 53 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $3.12 | n/a | 5 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.365 | n/a | 12 | Jun 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $0.3681 | n/a | 3 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $21.40 | n/a | 31 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.000001 | n/a | 7 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.70 | n/a | 3 | May 7, 2020 |
Cellectis
Sep 15, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.53
Upside: -
Relay Therapeutics
Aug 10, 2026
Reiterated: Buy
Price Target: $21 → $26
Current: $18.84
Upside: +38.00%
Taysha Gene Therapies
Jun 23, 2026
Reiterated: Buy
Price Target: $8 → $11
Current: $5.02
Upside: +119.12%
enGene Therapeutics
May 8, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.91
Upside: -
Intellia Therapeutics
Apr 28, 2026
Reiterated: Buy
Price Target: $28 → $30
Current: $12.14
Upside: +147.12%
CRISPR Therapeutics AG
Jan 30, 2026
Reiterated: Buy
Price Target: $86 → $80
Current: $56.56
Upside: +41.44%
Nuvation Bio
Nov 20, 2025
Reiterated: Buy
Price Target: $8 → $10
Current: $5.85
Upside: +70.94%
Benitec Biopharma
Nov 4, 2025
Reiterated: Buy
Price Target: $20 → $22
Current: $11.02
Upside: +99.64%
Foghorn Therapeutics
Oct 31, 2025
Reiterated: Buy
Price Target: $9
Current: $4.14
Upside: +117.39%
IDEAYA Biosciences
Oct 13, 2025
Reiterated: Buy
Price Target: $45
Current: $38.41
Upside: +17.16%
Sep 22, 2025
Reiterated: Buy
Price Target: $12 → $6
Current: $0.6178
Upside: +871.19%
Sep 17, 2025
Reiterated: Buy
Price Target: $13
Current: $1.85
Upside: n/a
Sep 12, 2025
Reiterated: Buy
Price Target: $15
Current: $8.91
Upside: n/a
Aug 15, 2025
Reiterated: Hold
Price Target: n/a
Current: $4.14
Upside: n/a
Jul 29, 2025
Reiterated: Buy
Price Target: $50
Current: $58.36
Upside: n/a
Jun 18, 2025
Reiterated: Buy
Price Target: $6
Current: $3.12
Upside: n/a
Jun 10, 2025
Reiterated: Hold
Price Target: n/a
Current: $0.365
Upside: n/a
Jun 3, 2025
Reiterated: Buy
Price Target: $4
Current: $0.3681
Upside: n/a
May 9, 2025
Downgraded: Hold
Price Target: n/a
Current: $21.40
Upside: n/a
Dec 27, 2024
Rated: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
May 7, 2020
Rated: Hold
Price Target: n/a
Current: $2.70
Upside: n/a